Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting Hepatic Encephalopathy 80% of people with chronic liver disease develop some form of HE 9 in 10 HE patient caregivers report "they did not realize what they were in for at the time of diagnosis" UnderstandingHE.com provides educational tools and resources to support patients and caregivers LAVAL, QC / ACCESSWIRE / October 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced its partnership with award-winning actor Bellamy Young, who is speaking out to help educate people who are impacted by hepatic encephalopathy (HE), caused by cirrhosis. Bellamy wants those affected to know they are not alone and to help them overcome stigma that can interfere with disease education.

Salix Pharmaceuticals Partners with Bellamy Young

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium presentation and four poster presentations during the American Academy of Optometry (AAOpt) annual meeting, which will take place in New Orleans Oct. 11-14, 2023. The podium presentation will highlight the results of a prospective, multi-center study that evaluated key clinical dry eye disease (DED) f.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

LAVAL, QC / ACCESSWIRE / September 29, 2023 / Bausch + Lomb Corporation ("Bausch + Lomb") (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies Inc. (the "Company" or "Bausch Health") (NYSE/TSX:BHC), today announced it has completed its acquisition of XIIDRA® (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets. Under the terms of the agreement, Bausch + Lomb, through an affiliate, acquired XIIDRA® and the other ophthalmology assets from Novartis for up to $2.5 billion, including an upfront payment of $1.75 billion in cash with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization.

Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has completed its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye, and certain other ophthalmology assets. In addition to XIIDRA, Bausch + Lomb's d.

Bausch + Lomb Completes Acquisition of XIIDRA®

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of LUMIFY EYE ILLUMINATIONS, a new line of hypoallergenic specialty eye care products scientifically developed to cleanse, nourish and brighten the sensitive eye area. “Many products contain chemicals or preservatives that can irritate the delicate area of and around the eye,” said John Ferris, e.

Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States

NEW YORK , Sept. 26, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Bausch Health Companies Inc..

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Bausch Health Companies Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 25, 2023 - (NYSE: BHC)

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between August 6, 2020 and May 3, 2023, both dates inclusive (the “Class Period”), of the important September 25, 2023 lead plaintiff deadline. SO WHAT: If you purchased Bausch securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W.

BHC DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action – BHC

LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE:BHC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 24, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE: BHC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

Azul

DISH Network

Plug Power

Peloton

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling Well-Known Buy-Rated Stocks Under $10 Could Explode Higher in October

LOS ANGELES , Sept. 22, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Bausch Health Companies Inc. ("Bausch" or the "Company") (NYSE: BHC).

BHC Investors Have Opportunity to Lead Bausch Health Companies Inc. Securities Fraud Lawsuit

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 25, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Bausch Health Companies Inc. (“Bausch” or the “Company”) (NYSE: BHC) securities between August 6, 2020 and May 3, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On May 4, 2023, Bausch released its first quarter 2023.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bausch Health Companies Inc. (BHC)

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bausch Health Companies Inc. (NYSE: BHC) between August 6, 2020 and May 3, 2023, both dates inclusive (the "Class Period"), of the important September 25, 2023 lead plaintiff deadline.

BHC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bausch Health Companies Inc. Investors to Secure Counsel Before Important September 25 Deadline in Securities Class Action - BHC

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch" or the "Company") (NYSE: BHC).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC

LOS ANGELES, CA / ACCESSWIRE / September 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bausch Health Companies Inc. ("Bausch" or "the Company") (NYSE:BHC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 6, 2020 and May 3, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 25, 2023.

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Bausch Health Companies Inc. with Losses of $100,000 to Contact the Firm

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?

Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez LAVAL, QC / ACCESSWIRE / September 21, 2023 / In honor of Hispanic Heritage Month, Bausch Health Companies Inc. (NYSE:BHC),(TSX:BHC) and its oral health care business, OraPharma, today announced its collaboration with the League of United Latin American Citizens (LULAC) - the largest and oldest Hispanic organization in the United States - to foster a greater understanding of gum disease detection, and treatment within the Hispanic community. Gum disease, also known as periodontal disease, is a chronic bacterial infection that affects nearly 65 million American adults and is even more common among Latinos.

League of United Latin American Citizens (LULAC) Joins OraPharma in the Fight Against Gum Disease

NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Bausch Health Companies Inc. ("Bausch" or the "Company") (NYSE: BHC) of a class action securities lawsuit.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Bausch Health Companies Inc.(BHC) Investors of a Class Action Lawsuit and Upcoming Deadline

Bausch Health stock fell on Tuesday on the news of its CFO unexpectedly leaving. Wednesday brought a bounce as investors viewed the sell-off as a buying opportunity.

Why Bausch Health Stock Is Jumping Today

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear contact lenses and use eye care materials every day, but many don't realize the environmen.

Bausch + Lomb's ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners

Tom Vadaketh is leaving as Bausch's CFO after less than two years with the company. Vadaketh helped oversee financial improvement for Bausch.

Why Shares of Bausch Health Companies Fell Tuesday

Bausch Health Cos. Inc. BHC, -1.76% shares fell nearly 3% premarket on Tuesday after the company announced late Monday that chief financial officer Tom Vadaketh has resigned effective Oct. 13 to pursue another opportunity.

Bausch Health shares fall after CFO resignation

Canopy Growth

Cronos Group

GrowGeneration Corp

Green Thumb Industries Inc.

Jazz Pharmaceuticals

Scotts Miracle-Gro

There's a reason people are looking for cannabis stocks to buy now. It is increasingly likely that marijuana will be rescheduled from a Schedule I controlled substance to a Schedule III controlled substance.

7 Cannabis Stocks to Buy BEFORE the Marijuana Rescheduling Boom

Bausch Health finance chief Tom Vadaketh will resign effective Oct. 13 to pursue another opportunity, the Canadian pharmaceutical company said in a regulatory filing Monday.

Bausch Health CFO Tom Vadaketh to resign effective Oct. 13

LAVAL, QC / ACCESSWIRE / September 18, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) ("BHC" or the "Company") today announced that Tom Vadaketh, Executive Vice President, Chief Financial Officer, has resigned from his role to pursue another opportunity, and will be leaving the Company effective October 13, 2023. The Company thanks Mr.

News for Bausch Health Companies Inc Stock (BHC)